ArticleThoracic cancer2024

Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).

Ou Yamaguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.